ZOGENIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-18: Form 8-K; Period of report 2013-12-17; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-12-10: Form 8-K; Period of report 2013-12-10; Description 8.01 Other Events; Details 8.01.
- 2013-12-05: Form 8-K; Period of report 2013-12-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-12-03: Form 8-K; Period of report 2013-11-26; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-18 | 8-K | 2013-12-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 17, 2013, Zogenix, Inc. (“Zogenix” or the “Company”) announced the appointment of Bradley S. Galer, M.D. as Executive Vice President and Chief Medical Officer, effective immediately. | d646698d8k.htm |
| 2013-12-10 | 8-K | 2013-12-10 | 8.01 Other Events | 8.01 On December 10, 2013, Zogenix, Inc. (“Zogenix”) announced that the U.S. Food and Drug Administration approved Zogenix’s supplemental New Drug Application for a 4 mg dose of Sumavel DosePro (sumatriptan injection) Needle-free Delivery System. | d640292d8k.htm |
| 2013-12-05 | 8-K | 2013-12-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Adoption of the Zogenix, Inc. Employment Inducement Equity Incentive Award Plan. | d642010d8k.htm |
| 2013-12-03 | 8-K | 2013-11-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 26, 2013, Zogenix, Inc. (the “Company”) entered into a Co-Marketing and Development Services Agreement (the “Co-Marketing Agreement”) with Battelle Memorial Institute (“Battelle”). | d636138d8k.htm |
| 2013-11-06 | 8-K | 2013-11-05 | 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.02 On November 5, 2013, Zogenix, Inc. (the “Company” or “Zogenix”) gave notice to Cantor Fitzgerald & Co. that it was terminating its Controlled Equity OfferingSM Sales Agreement, dated March 27, 2013 (the “Cantor Agreement”), pursuant to Section 12(b) of the Cantor Agreement. 8.01 On November 5, 2013, Zogenix entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated and Leerink Swann LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 26,666,667 shares (the “Shares”) of Common Stock. | d623897d8k.htm |
| 2013-11-04 | 8-K | 2013-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2013, Zogenix, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2013. | d622046d8k.htm |
| 2013-10-28 | 8-K | 2013-10-25 | 8.01 Other Events | 8.01 On October 25, 2013, the U.S. Food and Drug Administration (“FDA”) approved Zogenix, Inc.’s New Drug Application (“NDA”) for ZohydroTM ER (hydrocodone bitartrate) extended-release capsules, an opioid agonist, extended-release oral formulation of hydrocodone without acetaminophen, for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate. | d617778d8k.htm |
| 2013-10-02 | 8-K | 2013-10-01 | 8.01 Other Events | 8.01 On October 1, 2013, Zogenix, Inc. (“Zogenix”) announced that it had been informed by the U.S. Food and Drug Administration (“FDA”) that an action letter on the New Drug Application (“NDA”) for ZohydroTM ER (hydrocodone bitartrate) extended-release capsules could follow after a further delay of short duration. | d606688d8k.htm |
| 2013-08-29 | 8-K | 2013-08-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 26, 2013, Zogenix, Inc. (“Zogenix” or the “Company”) and Patheon UK Limited (“Patheon”) entered into an amendment (the “Amendment”) to the Manufacturing Services Agreement, dated February 28, 2013, by and between Zogenix and Patheon (the “Services Agreement”). | d593678d8k.htm |
| 2013-08-08 | 8-K | 2013-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2013, Zogenix, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2013. | d582448d8k.htm |
| 2013-06-27 | 8-K | 2013-06-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 27, 2013, Zogenix, Inc. (“Zogenix”) and Valeant Pharmaceuticals North America LLC (“Valeant”) entered into a co-promotion agreement (the “Agreement”). | d560943d8k.htm |
| 2013-06-24 | 8-K | 2013-06-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 18, 2013, the Compensation Committee (the “Committee”) of the Board of Directors of Zogenix, Inc. (the “Company”) approved a company-wide retention program and, pursuant to such program, awarded restricted stock units (“RSUs”) to the Company’s named executive officers listed below (“NEOs”). | d558079d8k.htm |
| 2013-06-19 | 8-K | 2013-06-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Zogenix, Inc. (the “Company”) held its annual meeting of stockholders on June 18, 2013. | d556136d8k.htm |
| 2013-06-04 | 8-K | 2013-05-29 | 2.05 Costs Associated with Exit or Disposal Activities | 2.05 On May 29, 2013, Zogenix, Inc. (“Zogenix” or the “Company”) commenced a restructuring of its workforce, resulting in a reduction in force of approximately 37%, or 55 employees, across all functional areas of the Company. | d550172d8k.htm |
| 2013-05-09 | 8-K | 2013-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2013, Zogenix, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2013. | d536782d8k.htm |
| 2013-05-02 | 8-K | 2013-05-02 | 8.01 Other Events | 8.01 On May 2, 2013, Zogenix, Inc. (the “Company” or “Zogenix”) announced positive top-line results from its extended Phase 1 clinical trial of Relday™, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia. | d530981d8k.htm |
| 2013-03-27 | 8-K | 2013-03-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 27, 2013, Zogenix Inc. (“Zogenix” or the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), under which the Company may, from time to time, sell shares of its common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $25.0 million through Cantor. | d511084d8k.htm |
| 2013-03-27 | 8-K | 2013-03-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d504959d8k.htm |
| 2013-03-21 | 8-K | 2013-03-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Pursuant to the Company’s Annual Incentive Plan (the “Plan”), each Named Executive Officer is eligible for a performance bonus based upon the achievement of certain corporate performance goals approved by the Board and, with respect to the Named Executive Officers other than the Company’s Chief Executive Officer, individual performance objectives. | d507908d8k.htm |
| 2013-03-15 | 8-K | 2013-03-15 | 2.02 Results of Operations and Financial Condition | 2.02 On March 15, 2013, Zogenix, Inc. issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2012. | d504813d8k.htm |
| 2013-03-01 | 8-K | 2013-02-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 On February 28, 2013, Zogenix, Inc. (“Zogenix” or the “Company”) and Patheon UK Limited (“Patheon”) entered into a manufacturing services agreement (the “Services Agreement”). | d494820d8k.htm |
| 2013-02-27 | 8-K | 2013-02-26 | 8.01 Other Events | 8.01 On February 26, 2013, Zogenix, Inc. (“Zogenix” or the “Company”) announced that it has been informed by the U.S. Food and Drug Administration (“FDA”) that the Company is unlikely to receive an action letter for its New Drug Application (“NDA”) for Zohydro ER (hydrocodone bitartrate extended-release capsules) by the Prescription Drug User Fee Act (“PDUFA”) goal date of March 1, 2013. | d493543d8k.htm |
| 2013-02-07 | 8-K | 2013-02-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 1, 2013, Arda M. Minocherhomjee, Ph.D. resigned from the Board of Directors (the “Board”) of Zogenix, Inc. (the “Company”). | d481689d8k.htm |
| 2013-01-07 | 8-K | 2013-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2013, Zogenix, Inc. (the “Company” or “Zogenix”) announced preliminary unaudited gross product sales for the quarter ended December 31, 2012. | d463054d8k.htm |
| 2013-01-03 | 8-K | 2013-01-03 | 8.01 Other Events | 8.01 On January 3, 2013, Zogenix, Inc. (the “Company” or “Zogenix”) announced positive single-dose pharmacokinetic (“PK”) results from the Phase 1 clinical trial of Relday™, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia. | d461275d8k.htm |